•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
UiPath Q1 Earnings In Line With Estimates, Revenues Increase Y/Y
MongoDB (MDB) Posts Strong Q1 Earnings Driven by Cloud Adoption and AI Momentum
The Smartest AI Money Is Buying Nebius
ARMOUR Residential REIT, Inc. Announces June 2026 Dividend Rate per Common Share
Palo Alto Networks: Why $6 Billion In ARR Is Just The Beginning
Glean Surpasses $300M ARR: Unrivaled Enterprise Context Fuels AI Adoption
Salesforce (CRM) Q1 Earnings: EPS Beat Amid Mixed Revenue Guidance
Vaunt Reaches $3.6 Million in ARR, Up 162% Year Over Year
Salesforce Heads into Earnings with Everything to Prove - And Everything to Gain
CVLT Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Filed Against Commvault Systems, Inc.
Agilysys (AGYS) Reports Strong Q4 Results and Optimistic FY27 Guidance
Earnings High Fliers And Busts
Cellebrite Announces First-Quarter 2026 Results
Trend Micro Reports Earnings Results for Q1 2026
Monthly-Paid Dividends, From 29 Ideal 'Safer' May Dogs
ACCESS Newswire Reports First Quarter 2026 Results
Tyler Technologies Q1 Earnings Beat Estimates, Revenues Rise Y/Y
Microsoft Reports Strong Q3 Results Despite Stock Decline